413 related articles for article (PubMed ID: 24812434)
1. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Hirakawa Y; Arima H; Zoungas S; Ninomiya T; Cooper M; Hamet P; Mancia G; Poulter N; Harrap S; Woodward M; Chalmers J
Diabetes Care; 2014 Aug; 37(8):2359-65. PubMed ID: 24812434
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.
Mohammedi K; Woodward M; Marre M; Colagiuri S; Cooper M; Harrap S; Mancia G; Poulter N; Williams B; Zoungas S; Chalmers J
Cardiovasc Diabetol; 2017 Jul; 16(1):95. PubMed ID: 28750645
[TBL] [Abstract][Full Text] [Related]
3. New insights from ADVANCE.
Chalmers J; Kengne AP; Joshi R; Perkovic V; Patel A
J Hypertens Suppl; 2007 Jun; 25(1):S23-30. PubMed ID: 17579315
[TBL] [Abstract][Full Text] [Related]
4. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
Zoungas S; de Galan BE; Ninomiya T; Grobbee D; Hamet P; Heller S; MacMahon S; Marre M; Neal B; Patel A; Woodward M; Chalmers J; ; Cass A; Glasziou P; Harrap S; Lisheng L; Mancia G; Pillai A; Poulter N; Perkovic V; Travert F
Diabetes Care; 2009 Nov; 32(11):2068-74. PubMed ID: 19651921
[TBL] [Abstract][Full Text] [Related]
5. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
[TBL] [Abstract][Full Text] [Related]
6. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
Zoungas S; Chalmers J; Neal B; Billot L; Li Q; Hirakawa Y; Arima H; Monaghan H; Joshi R; Colagiuri S; Cooper ME; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Lisheng L; Mancia G; Marre M; Matthews DR; Mogensen CE; Perkovic V; Poulter N; Rodgers A; Williams B; MacMahon S; Patel A; Woodward M;
N Engl J Med; 2014 Oct; 371(15):1392-406. PubMed ID: 25234206
[TBL] [Abstract][Full Text] [Related]
7. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial.
Hata J; Arima H; Rothwell PM; Woodward M; Zoungas S; Anderson C; Patel A; Neal B; Glasziou P; Hamet P; Mancia G; Poulter N; Williams B; Macmahon S; Chalmers J;
Circulation; 2013 Sep; 128(12):1325-34. PubMed ID: 23926207
[TBL] [Abstract][Full Text] [Related]
8. Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE.
Poulter NR
J Hypertens Suppl; 2009 May; 27(1):S3-8. PubMed ID: 19483505
[TBL] [Abstract][Full Text] [Related]
9. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation.
ADVANCE Management Committee
Diabetologia; 2001 Sep; 44(9):1118-20. PubMed ID: 11596665
[TBL] [Abstract][Full Text] [Related]
10. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.
Wong MG; Perkovic V; Chalmers J; Woodward M; Li Q; Cooper ME; Hamet P; Harrap S; Heller S; MacMahon S; Mancia G; Marre M; Matthews D; Neal B; Poulter N; Rodgers A; Williams B; Zoungas S;
Diabetes Care; 2016 May; 39(5):694-700. PubMed ID: 27006512
[TBL] [Abstract][Full Text] [Related]
11. ADVANCE: breaking new ground in type 2 diabetes.
Chalmers J; Perkovic V; Joshi R; Patel A
J Hypertens Suppl; 2006 Aug; 24(5):S22-8. PubMed ID: 16936533
[TBL] [Abstract][Full Text] [Related]
12. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
de Galan BE; Zoungas S; Chalmers J; Anderson C; Dufouil C; Pillai A; Cooper M; Grobbee DE; Hackett M; Hamet P; Heller SR; Lisheng L; MacMahon S; Mancia G; Neal B; Pan CY; Patel A; Poulter N; Travert F; Woodward M;
Diabetologia; 2009 Nov; 52(11):2328-2336. PubMed ID: 19688336
[TBL] [Abstract][Full Text] [Related]
13. Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
van Steen SC; Woodward M; Chalmers J; Li Q; Marre M; Cooper ME; Hamet P; Mancia G; Colagiuri S; Williams B; Grobbee DE; DeVries JH;
Diabetologia; 2018 Apr; 61(4):780-789. PubMed ID: 29308539
[TBL] [Abstract][Full Text] [Related]
14. The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE.
Lee AK; Woodward M; Wang D; Ohkuma T; Warren B; Sharrett AR; Williams B; Marre M; Hamet P; Harrap S; Mcevoy JW; Chalmers J; Selvin E
J Clin Endocrinol Metab; 2020 Jan; 105(1):152-62. PubMed ID: 31588504
[TBL] [Abstract][Full Text] [Related]
15. ADVANCE: action in diabetes and vascular disease.
Patel A; Chalmers J; Poulter N
J Hum Hypertens; 2005 Jun; 19 Suppl 1():S27-32. PubMed ID: 16075030
[TBL] [Abstract][Full Text] [Related]
16. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial.
Beulens JW; Patel A; Vingerling JR; Cruickshank JK; Hughes AD; Stanton A; Lu J; McG Thom SA; Grobbee DE; Stolk RP; ;
Diabetologia; 2009 Oct; 52(10):2027-36. PubMed ID: 19633827
[TBL] [Abstract][Full Text] [Related]
17. [ADVANCE study: objectives, design and current status].
Chalmers J
Drugs; 2003; 63 Spec No 1():39-44. PubMed ID: 12708881
[TBL] [Abstract][Full Text] [Related]
18. What matters in ADVANCE and ADVANCE-ON.
Hamet P
Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Long-term HbA
Sheng CS; Tian J; Miao Y; Cheng Y; Yang Y; Reaven PD; Bloomgarden ZT; Ning G
Diabetes Care; 2020 Jun; 43(6):1185-1190. PubMed ID: 32229597
[TBL] [Abstract][Full Text] [Related]
20. Prognostic importance of visit-to-visit blood pressure variability for micro- and macrovascular outcomes in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study.
Cardoso CRL; Leite NC; Salles GF
Cardiovasc Diabetol; 2020 May; 19(1):50. PubMed ID: 32359350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
